Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160025/S023

Astron Pulsar; Pulsar-18; Pulsar-18 T3

Biotronik AG · Decision date Dec 17, 2025

FDA DECISIONP160025/S023

What did the FDA decide?

FDA records P160025/S023 as a supplement to PMA P160025, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 17, 2025.

FDA approval order statement

new hydrogen content testing equipment
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Dec 17, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160025/S023
Regulatory pathway
PMA supplement
Applicant
Biotronik AG
Product code
NIP
Decision code
OK30
Decision date
Dec 17, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: STENT, SUPERFICIAL FEMORAL ARTERY.

Applicant
Biotronik AG
Product code
NIP
FDA device class
3

For the original device and its historical approval scope, see PMA P160025. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160025 · Original PMA

    ASTRON PULSAR STENT SYSTEM, PULSAR-18 STENT SYSTEM

  2. P160025/S022 · Related supplement

    Pulsar-18 T3 Stent System

  3. P160025/S023 received

    Application receipt date recorded by FDA.

  4. P160025/S023 · FDA decision

    30-Day Notice

  5. P160025/S024 · Related supplement

    Astron Pulsar Pulsar-18, Pulsar-18 T3

  6. P160025/S025 · Related supplement

    Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System

  7. P160025/S026 · Related supplement

    Pulsar-18 T3 Peripheral Self-Expanding Nitinol Stent System

Timeline entries are records held by MedtechLedger for P160025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160025

Product / regulatory recordCompanyPathwayDecision dateSource
Biotronik AGPMA approvalMar 23, 2017FDA
Biotronik AGPMA supplementOct 21, 2025FDA
Biotronik AGPMA supplementMar 10, 2026FDA
Biotronik AGPMA supplementJun 22, 2026FDA
Biotronik AGPMA supplementSep 11, 2026FDA

Explore the linked device profile

Other records with product code NIP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Ackerstrasse 6, Bülach, 8180

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records